Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AEON Biopharma, Inc. (AEON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: AEON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.2
1 Year Target Price $7.2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.95M USD | Price to earnings Ratio - | 1Y Target Price 7.2 |
Price to earnings Ratio - | 1Y Target Price 7.2 | ||
Volume (30-day avg) 1 | Beta 0.75 | 52 Weeks Range 0.38 - 1.45 | Updated Date 01/31/2026 |
52 Weeks Range 0.38 - 1.45 | Updated Date 01/31/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.01% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.16 | Enterprise Value 17492507 | Price to Sales(TTM) 97.16 |
Enterprise Value 17492507 | Price to Sales(TTM) 97.16 | ||
Enterprise Value to Revenue 201.68 | Enterprise Value to EBITDA -5.89 | Shares Outstanding 11643786 | Shares Floating 8196294 |
Shares Outstanding 11643786 | Shares Floating 8196294 | ||
Percent Insiders 19.11 | Percent Institutions 12.57 |
Upturn AI SWOT
AEON Biopharma, Inc.
Company Overview
History and Background
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for respiratory diseases. The company was founded to address unmet medical needs in this area, particularly for conditions like idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Key milestones would involve its formation, the initiation of clinical trials, and any significant preclinical or clinical data releases.
Core Business Areas
- Biopharmaceutical Development: AEON Biopharma, Inc. is primarily engaged in the research, development, and potential commercialization of novel therapeutics for respiratory diseases. Their focus is on innovative drug candidates aimed at addressing the underlying mechanisms of these conditions.
Leadership and Structure
AEON Biopharma, Inc. is led by a management team with experience in biopharmaceutical development and clinical trials. The specific organizational structure would include departments for research and development, clinical operations, regulatory affairs, and corporate functions. Detailed information on the current leadership team and board of directors can typically be found in their SEC filings.
Top Products and Market Share
Key Offerings
- Product Name 1: AEON-101 (potential candidate name) - A novel therapeutic agent being developed for idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic lung diseases. Specific market share data for pre-commercialization products is not applicable. Competitors include companies developing antifibrotic therapies for IPF such as Boehringer Ingelheim (with Ofev) and Roche (with Esbriet).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on rare and severe respiratory diseases, is characterized by high R&D costs, long development cycles, and significant unmet medical needs. The market is driven by scientific innovation, regulatory approvals, and the potential for blockbuster drugs to address large patient populations with limited treatment options.
Positioning
AEON Biopharma, Inc. is positioned as a clinical-stage biopharmaceutical company aiming to disrupt the treatment landscape for fibrotic lung diseases with potentially innovative therapeutic approaches. Its competitive advantage would lie in the novelty of its drug candidates and their potential to offer improved efficacy or safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for treatments for idiopathic pulmonary fibrosis and other fibrotic lung diseases is substantial, estimated to be in the billions of dollars globally. AEON Biopharma, Inc. is positioned to address a segment of this TAM if its lead candidate proves successful in clinical trials and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Focus on a significant unmet medical need in fibrotic lung diseases.
- Potential for novel therapeutic mechanisms.
- Experienced management team in biopharmaceutical development (assumed).
Weaknesses
- Clinical-stage company with no approved products.
- High R&D costs and long development timelines.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing understanding of fibrotic lung disease mechanisms.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Expansion into other fibrotic conditions beyond IPF.
- Emerging markets for advanced therapies.
Threats
- Clinical trial failures or delays.
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and stringent approval processes.
- Reimbursement challenges and pricing pressures.
Competitors and Market Share
Key Competitors
- Boehringer Ingelheim (US Stock Symbol: N/A - Private Company)
- Roche (US Stock Symbol: RHHBY)
- Gilead Sciences (US Stock Symbol: GILD)
Competitive Landscape
AEON Biopharma, Inc. faces a competitive landscape dominated by larger pharmaceutical companies with established products in the fibrotic lung disease market. Its primary disadvantage is its clinical-stage status and lack of commercialized products. Its advantage lies in the potential for a novel mechanism of action that could offer superior efficacy or a differentiated safety profile.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for AEON Biopharma, Inc. would be measured by the progression of its drug candidates through the clinical development pipeline and any increase in its operational scale. Significant financial growth is not expected until commercialization.
Future Projections: Future growth projections for AEON Biopharma, Inc. are contingent upon the successful completion of clinical trials, regulatory approvals, and subsequent market penetration of its therapeutic candidates. Analyst estimates would focus on potential peak sales and market adoption.
Recent Initiatives: Recent initiatives would likely include advancements in clinical trial phases, potential new drug candidate discovery, or strategic collaborations aimed at accelerating development or expanding the company's pipeline.
Summary
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company with a strong focus on addressing unmet needs in fibrotic lung diseases. Its primary strength lies in its potential for innovative therapeutic development. However, it faces significant risks inherent in drug development, including clinical trial failures and intense competition. The company needs to successfully navigate regulatory hurdles and secure funding to advance its pipeline towards commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, S-1)
- Industry Market Research Reports
- Biopharmaceutical News Outlets
- Financial Data Providers
Disclaimers:
This analysis is based on publicly available information and industry knowledge. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share and TAM figures are estimates and can vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AEON Biopharma, Inc.
Exchange NYSE MKT | Headquaters Irvine, CA, United States | ||
IPO Launch date 2021-04-12 | President, CEO & Director Mr. Robert Bancroft | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.aeonbiopharma.com |
Full time employees 5 | Website https://www.aeonbiopharma.com | ||
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.